At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
The purpose of this study is to find the highest dose of the investigational drug STK-012 that can be given safely in combination with pembrolizumab immunotherapy to people with solid tumors that have spread or come back despite prior treatment. STK-012 is a modified form of a protein called interleukin-2, which is normally made by the immune system. It may help to multiply and activate tumor-killing cells of the immune system.
-
To learn more about the purpose of this study and to find out who can join, please click here for Substudy 01A or here for Substudy 01C to visit ClinicalTrials.gov for a full clinical trial description.
-
The purpose of this study is to see if delivering laser light directly to the prostate to activate a light-sensitive drug is a safe and effective treatment for prostate cancer that has come back after radiation therapy. The goal of this treatment is to eliminate any remaining prostate cancer cells. This approach is a form of photodynamic therapy (PDT).
-
Researchers in this study want to determine if combining the drug venetoclax with standard chemotherapy may be more effective than standard chemotherapy alone in children and adolescents with relapsed acute myeloid leukemia (AML). Venetoclax blocks Bcl-2, a protein that helps cancer cells to survive and resist the effects of cancer treatments. By blocking Bcl-2, venetoclax may kill cancer cells and/or make other treatments more effective.
-
Researchers are comparing RMC-6236 with standard therapy in people with advanced pancreatic cancer. The people in this study have pancreatic cancer that has metastasized (spread) and keeps growing even after treatment.
-
Acute lymphoblastic leukemia (ALL) in infants (babies under 1 year of age) can be challenging to treat. Researchers in this study are assessing the addition of 2 new drugs to standard chemotherapy for ALL in infants.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
This protocol will provide expanded access to treatment with the investigational drug L-MTP-PE for people with osteosarcoma. L-MTP-PE works by activating certain types of white blood cells, and these active white blood cells help the immune system to kill cancer cells. L-MTP-PE is given intravenously (by vein).
- A Study of LY4257496 in People With Solid Tumor Cancer
Full Title OMNIRAY, A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults with GRPR-Positive Advanced Solid Tumors
Purpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Komal Jhaveri’s office at 646-888-4226.
Protocol
25-361Phase
Phase I (phase 1)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT07114601ClinicalTrials.gov
-
Researchers are seeing how well the drug FORE8394 works in people with advanced solid tumors, including brain tumors. The people in this study include adults and children with cancers that keep growing or came back even with treatment. Their tumors have mutations (changes or variants) in the BRAF gene.